Is­raeli API mak­er Wave­length buys up ma­jor­i­ty stake in In­di­an firm mak­ing drug start­ing ma­te­ri­als and in­ter­me­di­ates

As the Covid-19 pan­dem­ic con­tin­ues to chal­lenge the glob­al drug sup­ply chain, na­tions are look­ing for new ways to en­able na­tive pro­duc­ers to con­tin­ue scal­ing up. Now, an Is­raeli API mak­er is drop­ping a down pay­ment in­to an In­di­an in­ter­me­di­ates com­pa­ny to ramp up its own man­u­fac­tur­ing base.

Wave­length Phar­ma­ceu­ti­cals will pay an undis­closed sum to buy up a ma­jor­i­ty stake in Hy­der­abad’s Vana­mali Or­gan­ics, an In­di­an firm spe­cial­iz­ing in mak­ing drug in­ter­me­di­ates and start­ing ma­te­ri­als that will add to Wave­lengths’ API con­tract man­u­fac­tur­ing work, the com­pa­ny said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER